Johnson & Johnson (NYSE:JNJ) Trading Down 1.7% - Should You Sell?

Key Points

• JNJ shares fell 1.7% on Monday, trading as low as $248.63 after closing at $253.04, though volume was only slightly below average.
• Recent fundamentals remain strong: the company beat Q2 2026 earnings and revenue estimates, raised full-year guidance, and posted 6.6% year-over-year revenue growth.
• Wall Street stays constructive on Johnson & Johnson, with a consensus Moderate Buy rating and an average price target of about $265.30, supported by its dividend, balance sheet, and defensive appeal.

Johnson & Johnson (NYSE:JNJ - Get Free Report)'s stock price fell 1.7% on Monday . The company traded as low as $248.63 and last traded at $248.83. 8,109,336 shares traded hands during trading, a decline of 4% from the average daily volume of 8,458,165 shares. The stock had previously closed at $253.04.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported robust Q2 2026 results, beating expectations on both earnings and revenue, and raised its full-year 2026 guidance, reinforcing confidence in its growth outlook. Article: Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?
• Positive Sentiment: Recent coverage highlighted JNJ as one of the large-cap names quietly trading near 52-week or all-time highs, suggesting investors are rotating into defensive, high-quality stocks outside of the AI trade. Article: 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama (JNJ)
• Positive Sentiment: Analysts and commentators remain constructive on J&J’s long-term profile, pointing to its diversified business, strong balance sheet, and durable dividend history as reasons the stock can continue compounding. Article: Guggenheim Reiterates Buy Rating for Johnson & Johnson NYSE: JNJ

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research reports. JPMorgan Chase & Co. upped their price target on Johnson & Johnson from $250.00 to $260.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 15th. Guggenheim reaffirmed a "buy" rating and issued a $270.00 price objective on shares of Johnson & Johnson in a research note on Friday. Leerink Partners upgraded Johnson & Johnson from a "market perform" rating to an "outperform" rating and set a $265.00 price objective on the stock in a report on Wednesday, May 13th. Sanford C. Bernstein increased their target price on Johnson & Johnson from $225.00 to $251.00 and gave the stock a "market perform" rating in a research note on Wednesday, April 15th. Finally, Argus raised their target price on Johnson & Johnson from $240.00 to $275.00 and gave the company a "buy" rating in a report on Thursday, April 16th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $265.30.

Johnson & Johnson Price Performance

The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The company has a market cap of $598.99 billion, a PE ratio of 28.83, a PEG ratio of 2.39 and a beta of 0.24. The company's 50-day simple moving average is $239.82 and its 200 day simple moving average is $234.82.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The company's revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 11.68 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.2%. Johnson & Johnson's dividend payout ratio (DPR) is currently 62.11%.

Insider Activity at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.16% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares during the last quarter. United Bank increased its holdings in Johnson & Johnson by 110.7% in the first quarter. United Bank now owns 9,279 shares of the company's stock valued at $1,539,000 after buying an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC raised its stake in Johnson & Johnson by 13.4% in the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company's stock valued at $896,000 after buying an additional 692 shares in the last quarter. Wealth Group Ltd. lifted its holdings in Johnson & Johnson by 12.8% during the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company's stock worth $226,000 after buying an additional 168 shares during the last quarter. Finally, Schnieders Capital Management LLC. boosted its position in shares of Johnson & Johnson by 9.8% during the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company's stock worth $11,255,000 after acquiring an additional 6,584 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.